BOLT — Bolt Biotherapeutics Balance Sheet
0.000.00%
- $8.42m
- -$19.09m
- $7.70m
Annual balance sheet for Bolt Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 186 | 169 | 102 | 47.3 | 27.5 |
| Net Total Receivables | — | — | — | 1.17 | 0.973 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 189 | 173 | 106 | 50.8 | 30.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 30.6 | 28.5 | 24.1 | 24.9 | 20.5 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 308 | 228 | 160 | 99.6 | 56.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 21.3 | 23.1 | 20.5 | 15.9 | 8.44 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 57.6 | 56.3 | 47 | 42.4 | 30.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 250 | 172 | 113 | 57.2 | 26.5 |
| Total Liabilities & Shareholders' Equity | 308 | 228 | 160 | 99.6 | 56.7 |
| Total Common Shares Outstanding |